Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells

Cancer Research

Volumn 62, Issue 1, 2002, Pages 188-199

  Yu, Chunrong ^a   Krystal, Geoffrey ^a   Varticovksi, Lyuba ^a   McKinstry, Robert ^a   Rahmani, Mohamed ^a   Dent, Paul ^a   Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; BCR ABL PROTEIN; CASPASE 3; CYTOCHROME C OXIDASE; ENZYME PRECURSOR; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; PROTEIN P44; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; LETHALITY; LEUKEMIA CELL; MONONUCLEAR CELL; ONCOGENE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ACTIVATING TRANSCRIPTION FACTOR 1; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CDC2 PROTEIN KINASE; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG SYNERGISM; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; G0 PHASE; G1 PHASE; HL-60 CELLS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; K562 CELLS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MILK PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; U937 CELLS;

EID: 0036142963     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. The chronic myelogenous leukemia-specific P210 protein is the product of the Bcr/Abl hybrid gene
2. Heterogeneity of chromosome 22 breakpoint in Philadelphia-positive (Ph+) acute lymphocytic leukemia
3. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
4. The BCR gene and Philadelphia chromosome-positive leukemogenesis
5. Induction of chronic myelogenous leukemia in mice by the p210 bcr/abl gene of the Philadelphia chromosome
6. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL
7. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents
8. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: Protection is correlated with upregulation of Bcl-xL
9. A requirement for NF-κB activation in Bcr-Abl-mediated transformation
10. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
11. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
12. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCRABL tyrosine kinase, CGP 57148
13. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
14. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells
15. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs
16. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase
17. Mammalian MAP kinase signalling cascades
18. MAP kinase pathways
19. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
20. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo
21. Identification of a novel inhibitor of mitogen-activated protein kinase kinase
22. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
23. Evidence for involvement of mitogenactivated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-β-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling
24. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: Inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin
25. MEK inhibition enhances paclitaxel-induced tumor apoptosis
26. Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937)
27. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation
28. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line
29. The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells
30. Characterization of a K562 multidrug-resistant cell line
31. Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-β-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis
32. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-β-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2
33. Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression
34. Functional cooperation between JunD and NF-κB in rat hepatocytes
35. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
36. Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals
37. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
38. Cotreatment with STI-571 enhances tumor necrosis factor a-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells
39. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571
40. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABLpositive chronic myelogenous leukemia cells
41. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents
42. Co-treatment with As203 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells
43. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling
44. Role of ERK activation in growth and erythroid differentiation of K562 cells
45. The tyrosine kinase inhibitor CGP 57148 (STI 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X
46. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway
47. Arsenic induces apoptosis of multi-drug resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2 or Bcl-x(L)
48. Geldanamycin and its analog 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human blasts
49. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic leukemia cells
50. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro
51. Conversion of Bcl-2 to a Bax-like death effector by caspases
52. Expression of the antiapoptotic MCL1 gene product is regulated by a mitogen activated protein kinase-mediated pathway triggered through microtubule disruption and protein kinase C
53. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL
54. Bcr/Abl activates transcription of the Bcl-X gene through STAT5
55. Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocytemacrophage colony-stimulating factor-delayed apoptosis in human neutrophils
56. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms
57. Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage
58. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
59. Mechanisms of resistance to the tyrosine kinase inhibitor STI571 and prospects for circumvention by combination with conventional chemotherapeutic agents
60. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
61. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to α1-acid glycoprotein in humans
62. Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571